With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

See which workplaces made this year's list.

2025_GPTW_ManufacturingProduction_Large_Altria Group_US1__685d54bb4f22a2fc232770e0_5

Employees say:"Altria has admirable workplace flexibility, and Altria was trailblazing the path of workplace flexibility even before COVID started. Those who are able to do their jobs fully remotely can work remotely without judgement, and those with roles that sometimes need to be in person (such as engineering) are still given the flexibility to work hybrid if they don't need to be in person that day. This aspect of the culture alone has been a game changer for me and many of my coworkers—especially those who would have long commutes, those who are parents, those who have health conditions, and those who have pets—and it has led to increases in productivity, better retention, and greater employee satisfaction."

Best Large Workplaces in Manufacturing and Production

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

GPTW Manufacturing & Production Large 2024-Altria Group

Employees say:"Altria is incredible place to work. I have had the fortunate experience to always have great supervisors/bosses. The leadership team at Altria throughout the years has been outstanding. I have made the most incredible friendships here. The people are wonderful and I have never met an employee/colleague that if you reached out and asked for help, they didn't provide it, get you to the right resource, etc."

Fortune partners with global people analytics firm Great Place to Work to analyze survey feedback representing employees from companies across the U.S.

GPTW-Millennials-Large-2024-Altria-Group

Employees say:"Altria is more than a company—it feels like a family to me. Managers are committed to inclusion, and they have always been supportive in helping me reach my full potential. My peers are also supportive in helping me to continuously learn and grow so that we can reach our full potential as a team. At the highest level, it's the people and leadership that make this place a great place to work."

100 Best Large Workplaces for Millennials

Industries included in the sector are beverages, food consumer products, and food production.

Fortune Sector Leaders: Food, Beverages, and Tobacco

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

GPTW Manufacturing Production Large 2023-Altria Group

Employees say: 
 
"The culture and relationships I have with my leaders, peers, and key stakeholders. We believe in each other and trust each other to get the work completed. My leaders are inspiring and allow me to bring my full self to work. They give me the autonomy to do my work and make decisions."

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Best-Workplaces-Large-Manufacturing-Production-2021-Altria-Group

Employees say: 
 
“The people are fantastic. I recently started working here and the authentic willingness to talk to, help and educate me on the company and industry has been amazing. Their concern for their employees, our physical and mental health is always at their forefront - whether it is to talk, educate or provide us with some space to deal with the issues that are affecting our society.”

This year’s Fortune 500 marks the 68th running of the list.

Companies on this year's list—which span the electrical, automotive, and medical device industries—invest in and trust their employees.

Employees say: 
 
“Everyone cares for each other. When you come to work in an environment like this, you can accomplish anything. Having your peers' and superiors' support and encouragement makes a huge difference.”

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-138-Altria Group

Operating just outside of Richmond, Va., Altria Group is one of the world's largest producers and marketers of tobacco and cigarettes.

We surveyed tens of thousands of employees to create this list of millennials’ favorite workplaces.

Best Large Workplaces Millennials 2021-Altria Group

Employees say: 
 
“Everyone cares for each other and when you come to work in an environment like this you can accomplish anything. Having your peers and superiors support and encouragement makes a huge difference.”

This year's Fortune 500 marks the 66th running of the list.

F500-2020-167-Altria

The holding company is the parent of tobacco giant Philip Morris USA and the U.S. Smokeless Tobacco Company. Altria also owns wine company Ste. Michelle Wine Estates, which includes wineries Columbia Crest and Chateau Ste. Michelle.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fortune Global 500

Best Workplaces In Manufacturing And Production

Founded

Industry Vertical

Sites

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Altria Group is one of the world’s largest tobacco companies, holding a diverse portfolio across combustible tobacco products, such as those made by Philip Morris USA, as well as smoke-free alternatives, like those from Njoy. Altria is also invested in complementary assets such as beer behemoth AB InBev and cannabinoid company Cronos Group. Altria’s focus is to support consumers as they move beyond smoking and transition to potentially less harmful choices.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Altria Group (MO): Company Profile, Stock Price, News, Rankings

legacy

Altria Group

altria group

Good day, and welcome to the Altria Group 2024 4th Quarter and Full Year Earnings Conference Call. Today's call is scheduled to last about 1 hour, including remarks by Altria Management and a question and answer session. I would now like to turn the call over to Mac Livingston, Vice President of Investor Relations for Altria Client Services. Please go ahead, sir.

Thanks, Shelby. Good morning, and thank you for joining us. This morning, Billy Gifford, Altria's CEO and Sal Mancuso, our CFO, will discuss Altria's 4th quarter and full year business results. Earlier today, we issued a press release providing our results. The release, presentation, quarterly metrics and our latest corporate responsibility reports are all available at altria.com.

During our call today, unless otherwise stated, we're comparing results to the same period in 2023. Our remarks contain forward looking statements, including projections of future results. Please review the forward looking and cautionary statement section at the end of today's earnings release for various factors that could cause actual results to differ materially from projections. Future dividend payments and share repurchases remain subject to the discretion of our Board of Directors. We report our financial results in accordance with U.

S. Generally accepted accounting principles. Today's call will contain various operating results on both a reported and adjusted basis. Adjusted results exclude special items that affect comparisons with reported results. Descriptions of these non GAAP financial measures and reconciliations to the most comparable GAAP financial measures are included in today's earnings release and on our website at altria.com.

Finally, all references in today's remarks to tobacco consumers or consumers within a specific tobacco category or segment refer to existing adult tobacco consumers 21 years of age or older. With that, I'll turn the call over to Billy.

Thanks, Mac. Good morning and thank you for joining us. 2024 was another pivotal year for Altria, headlined by meaningful progress toward our vision, strong financial results and significant cash returns to shareholders. Our company's leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future. For the full year, we grew adjusted diluted earnings per share by 3.4 percent and continued our long history of rewarding shareholders with over $10,200,000,000 in dividends and share repurchases.

As the year progressed, our innovative smoke free products, Enjoy In On, demonstrated encouraging performance through volume and share growth in their respective categories. And we hit meaningful milestones that help solidify our smoke free portfolio and position us for sustained success.

Shelby, we're having an issue with hearing the music still for those listening.

All right. And thank you. One moment. Thank you for your patience in holding. The issue has been resolved.

Speakers, you may proceed with your conference.

Thanks, Shelby. We apologize for the technical difficulties, and we'll start over again without the music. So good morning, and thank you for joining us. This morning, Billy Gifford, Altria's CEO and Sal Mancuso, our CFO, will discuss Altria's 4th quarter and full year business results. Earlier today, we issued a press release providing our results.

The release, presentation, quarterly metrics and our latest corporate responsibility reports are all available at altria.com. During our call today, unless otherwise stated, we're comparing results to the same period in 2023. Our remarks contain forward looking statements, including projections of future results. Please review the forward looking and cautionary statement section at the end of today's earnings release for various factors that could cause actual results to differ materially from projections. Future dividend payments and share repurchases remain subject to the discretion of our Board of Directors.

We report our financial results in accordance with U. S. Generally Accepted Accounting Principles. Today's call will contain various operating results on both a reported and adjusted basis. Adjusted results exclude special items that affect comparisons with reported results.

Descriptions of these non GAAP financial measures and reconciliations to the most comparable GAAP financial measures are included in today's earnings release and on our website at altria.com. Finally, all references in today's remarks to tobacco consumers or consumers within a specific tobacco category or segment refer to existing adult tobacco consumers 21 years of age or older. With that, I'll turn the call over to Billy.

Thanks, Mac. Good morning and thank you for joining us.

2024 was another pivotal year for Altria, headlined by meaningful progress toward

our vision, strong financial results and significant cash returns to our shareholders. Our company's leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future. For the full year, we grew adjusted diluted earnings per share by 3.4% and continued our long history of rewarding shareholders with over $10,200,000,000 in dividends and share repurchases. As the year progressed, our innovative smoke free products Enjoy and On demonstrated encouraging performance through volume and share growth in their respective categories. And we hit meaningful milestones that help solidify our smoke free portfolio and position us for sustained success in the U.

S. Nicotine space, including Enjoy receiving the 1st and only marketing granted orders from the FDA for menthol e vapor products, submitting PMTA applications to the FDA for next generation Enjoy and ON products, continuing preparations to commercialize Plume through our joint venture with JT and advocating for a responsible and well regulated marketplace, including stepped up enforcement against illicit market activity. My remarks this morning will focus on our view of the U. S. Nicotine space, our smoke free progress and our earnings guidance for 2025.

I'll then hand it over to Sal, who will provide an update on consumer and industry dynamics, further detail on our smokeable business and financial results. Let's begin with the operating environment and our view of the nicotine space. The potential for tobacco harm reduction in the U.

S. Is significant and consumers are seeking smoke free alternatives at a faster pace than we've seen historically.

In fact, over the past year, the estimated number of adult consumers in the e vapor and oral tobacco categories grew to approximately 28,000,000, nearly as large as the adult smoker population. We estimate that smoke free alternatives represented approximately 45% of the total nicotine space, up 5 percentage points from the prior year. For the total nicotine space, industry equivalized nicotine volumes increased for the 2nd consecutive year and grew by approximately 2% over the past 5 years on a compounded annual basis. The growing adoption of smoke free alternatives is encouraging The growing adoption of

smoke free alternatives is encouraging and directly aligned with our vision and the growth aspirations of

our smoke free businesses. In addition, decades of deliberate actions to prevent youth tobacco use are yielding results. And underage tobacco usage rates are at historic lows. Together, these trends are very encouraging for public health and the harm reduction opportunity. However, the primary driver of industry and smoke free growth continues to be the widespread availability of illicit disposable e vapor products, which is jeopardizing the long term opportunity for tobacco harm reduction.

We estimate that the e vapor category grew by approximately 30% in 2024 and that illicit products represent more than 60% of the category. At year end, we estimate that there were 20,000,000 vapers, up nearly 20% from the prior year, driven exclusively by disposable vapers. Our data also show that approximately 40% of the growth in disposable vapers came from those with no prior cigarette usage. It has become clear that 2 markets exist in the U. S, one for those who operate within the regulatory framework and one for those who flagrantly violate and evade the rules.

In the simplest terms, we believe the regulatory structure is broken and the tobacco marketplace is not operating as Congress intended. The FDA has not authorized enough smoke free products to meet consumer demand with legal products and regulators are not holding bad actors accountable. Illicit product manufacturers, distributors and retailers have yet to experience any material consequences for violating federal laws and regulations. This dynamic continues to make the operating environment challenging for responsible manufacturers and retailers and is confusing for consumers seeking FDA authorized products. In 2023, we introduced our 20 28 enterprise goals to more clearly define where we are headed.

We believe that our deep understanding of adult tobacco consumers, our comprehensive smoke free portfolio and our industry leading capabilities would help make them a reality. When we established these goals, we were aware of a small illicit e vapor market, not dissimilar from illicit markets in other tobacco categories throughout our history. However, the illicit e vapor market has grown to a size and scale beyond our expectations. We believe this dynamic compromises our ability to achieve our 20 28 smoke free volume and revenue goals. In addition, we believe it compromises our ability to achieve the Enjoy specific financial targets we established in connection with that transaction.

As a result, we are reassessing these smoke free goals and enjoy targets and anticipate providing updates when we have more clarity on how the legitimate e vapor market may evolve. We will be looking for signs of material progress, such as a decline in the illicit growth in the growth of illicit products, a meaningful increase in the number of illicit products prevented from entering the U. S. And DOJ or state AGs bringing litigation against illicit manufacturers, distributors and importers. Encouragingly, earlier this month, 9 state AGs and the District of Columbia announced various actions against illicit e vapor importers, distributors and retailers.

We also believe the FDA can restore order to the market by authorizing more PMTAs to establish a legal market of alternatives for consumers and by partnering with other federal agencies to prevent illicit products from entering the country. I am optimistic that these issues can and will be addressed. Let me be clear, we remain steadfast in our commitment to our vision and to building a portfolio of FDA authorized smoke free products for adult smokers and adult consumers currently using smoke free products. This update to our 20 28 enterprise goals does not impact our corporate financial goals or long term growth goals. And our progress on our goals can be found in the earnings release we issued this morning.

Let's now transition to our smoke free performance beginning with Enjoy. 2024 was a year of growth and learning for Enjoy and we are pleased with its performance in the context of the broader e vapor market as Enjoy grew volume and share in a competitive pod segment. Enjoy's progress was driven by several actions taken throughout the year, which I'll briefly highlight. In 2024, Enjoy expanded distribution base to over 100,000 stores, secured premium position at retail and more than 80% of contracted stores through Enjoy's first trade program, executed a variety of trial generating activities with compelling results and introduced a new brand equity campaign with impactful consumer messaging. As a result of these efforts, Enjoy consumables shipment volume grew by more than 15% to 12,800,000 units in the 4th quarter.

Consumables shipment volume for the full year was 46,600,000 units. And Enjoy device shipment volume for the Q4 grew by more than 22% to 1,100,000 units and was 5,000,000 units for the full year. In the Q4, Enjoy's retail share of consumables was 6.4 share points, up 2.8 share points versus the year ago period. Enjoy grew its share of consumables by 0.2 of a share point sequentially, while the retail price increased by over 20%, indicating strong demand for the brand. Before moving on, I'll mention the litigation before the U.

S. International Trade Commission. Yesterday, the ITC issued its final determination in Juul's case against injury. The ITC agreed with Juul's claims with respect to the 4 patents in this case. We disagree with the ITC's decision and continue to believe that JUUL's patents are invalid and that ACE does not infringe on these patents.

As a remedy, the ITC issued an exclusion order and cease and desist orders barring the importation and sale of ACE. The ITC's decision is currently under a 60 day review period by the Office of the US Trade Representative, which could reject the ITC's decision. Enjoy continues work on its product solution that addresses all of the patents at issue in the event the ITC's decision is not rejected. This decision would severely limit FDA authorized choices, including the only FDA authorized menthol e vapor products and undermines public health, especially in context of a market that is overrun by illicit products. Regarding Injoy's case against JUUL, in December, the administrative law judge issued an initial determination finding that Juul's products did not infringe on Enjoy's patents.

We have petitioned the ITC to review and reverse the ALJ's initial determination. We expect the ITC to issue a final determination in early April. Moving to the oral tobacco category. In the Q4, oral nicotine pouches grew 9.6 share points versus the prior year and represented over 45% of the category. Oral nicotine pouches were the primary contributor to the estimated 8% increase in oral tobacco industry volume over the past 6 months.

Helix continued to participate in the category growth as on reported shipment volume grew by more than 44% year over year to nearly 44,000,000 cans in the 4th quarter. ORN performed well at retail, growing its share of the oral tobacco category by 2 share points year over year to 8.9% in the 4th quarter. Born retail share was unchanged sequentially despite reduced promotional investments and increased competitive pressure. Consumer Loyalty for ON continues to build an approximately 800,000 consumers regularly purchased Oren in the 4th quarter, an increase of more than 40% versus the prior year. This growth included increased sourcing from competitive pouch brands.

1's performance was enabled by a variety of strategic investments Helix made throughout the year, including a new trade program that created broader visibility and secured premium fixture position for nearly 80% of Oren's volume and a fresh new look for Oren packaging and the its own equity campaign to further differentiate the brand. As a result of these efforts, Helix achieved profitability for the first time in the Q4 ahead of its 2025 goal. And we anticipate Helix will be profitable for the full year 2025. Outside of the U. S, Oran Plus is competing in the nicotine pouch space in Sweden and the United Kingdom.

In both markets, Olin plus has been incremental to our total portfolio, sourcing mainly from competitive brands. Olin plus's Flex Tek pouch offers a unique product experience and we are encouraged by the steady momentum that ON plus is building at retail and on e commerce. We are using consumer insights to inform our plans and we are launching 2 new flavors, raspberry lemon and watermelon mint in both markets to appeal to evolving consumer preferences. We look forward to bringing On Plus to the U. S.

Once authorized. In heated tobacco, we believe we are developing a portfolio of products that will appeal to adult smokers seeking innovative inhalable alternatives to e vapor products. We are moving forward with regulatory preparations to bring heated tobacco stick products to the U. S. Through Horizon, our joint venture with JT.

During 2024, we made great progress towards our PMPA and accelerated our work on an MRTPA submission for Plume. We now expect to make a combined submission in mid year 2025. And in December, we commenced a small scale test launch of SWIC, our heated tobacco capsule product through e commerce in Great Britain. We expect to use consumer insights from the test to further inform our strategies. Turning to our 2025 financial outlook.

We remain committed to tobacco harm reduction in the U. S. And continue to believe there is a significant opportunity to shift millions of smokers to FDA authorized smoke free alternatives. Our planned investment areas include market activities in support of our smoke free products and continued smoke free product research, development and regulatory preparations. We believe the external environment will remain dynamic in 2025.

And we will continue to monitor the economy, including the cumulative impact of inflation, tobacco consumer dynamics, including purchasing patterns and adoption of smoke free products, illicit product enforcement and regulatory litigation and legislative developments. Considering these factors, we expect to deliver 2025 full year adjusted diluted EPS in a range of $5.22 to $5.37 This range represents an adjusted diluted EPS growth rate of 2% to 5% from a $5.12 base in 20.24. Our guidance includes the impact of 1 fewer shipping day in 20 25, which occurs in the 4th in the Q1, assumes a limited impact on combustible and e vapor product volumes from enforcement efforts in the illicit e vapor market and includes the reinvestment of anticipated cost savings related to our previously announced optimize and accelerate initiative. In addition, the guidance range includes lower expected net periodic benefit income. I'd also like to welcome Rich Stoddart to our Board of Directors as announced this morning.

Mr. Stoddart's extensive global marketing and executive leadership experience will be a tremendous asset to Altria. I'll now turn it over to Sal to provide additional detail on our business and financial results.

Thanks, Billy. Our core tobacco businesses generated solid financial performance again this year in a challenging external environment. The smokeable product segment delivered on its strategy of maximizing profitability, while appropriately balancing investments in Marlboro with funding the growth of smoke free products. The segment grew its adjusted operating company's income by 5.5% in the 4th quarter and by 2% for the full year. Adjusted OCI margins expanded to 61.2% 61.6% for the Q4 and full year respectively.

This performance was supported by robust net price realization of 11.3% for the quarter and 10.1% for the full year. Smokeable Products segment reported domestic cigarette volumes declined 8.8% in the 4th quarter and 10.2% for the full year. When adjusted for calendar differences and trade inventory movements, domestic cigarette volumes for the Q4 and the full year declined by an estimated 11%. At the industry level, we estimate that adjusted domestic cigarette volumes declined by 8% in the 4th quarter and 9% for the full year. As Billy described, the pace of change within the nicotine space has been rapid over the past 2 years.

These changes have resulted in significant shifts in adult tobacco consumer preferences, with an increasing number of adult consumers entering the nicotine category, primarily through smoke free products. We have been monitoring these shifts and their effects on cigarette industry decline rates and are making 2 updates to our latest cigarette category decomposition estimates. First, we believe that the cigarette category secular decline estimate of 2.5% represents the impact to cigarette industry volume due to the decline in adult smokers excluding any cross category movement. 2nd, we estimate cross category impacts contributed approximately 3% to 4% to the cigarette industry decline over the last 12 months. Turning now to share dynamics.

Total discount segment share grew by 1.7 share points in the 4th quarter and by 1.3 share points for the full year with most of the growth coming from deep discount. Marlboro retail share of the cigarette category declined 1 share point in the 4th quarter and 0.3 share points sequentially, consistent with the recent historical seasonality in the 4th quarter. Within the highly profitable premium segment, Marlboro expanded its share of premium to 59.4 percent for the 4th quarter, an increase of 0.1 share point year over year and sequentially. For the full year, Marlboro grew its share of premium to 59.3%, an increase of 0.4 share points versus the prior year. We believe that Marlboro remains the aspirational brand in the cigarette category, and we are encouraged by its performance in 2024.

In cigars, reported shipment volume increased 2.9% in the 4th quarter. Middleton continued to contribute to smokeable products segment financial results and black and mild remain the leader in the highly profitable machine made large tip cigar segment. The Oral Tobacco Products segment reported strong 4th quarter results. Adjusted OCI and adjusted OCI margins increased and ON grew its retail share of the oral tobacco category year over year. For the Q4, adjusted OCI grew 13% and the segment expanded percent, an impressive increase of 6.4 percentage points versus the prior year.

For the full year, the segment grew adjusted OCI by 5.2 percent with adjusted OCI margins of 67.8%, up 0.4 percentage points. Total segment reported shipment volume decreased by 0.4% and 1% for the Q4 and full year respectively. When adjusted for trade inventory movements and calendar differences, segment volumes were essentially unchanged for the Q4 and declined by an estimated 2% for the full year. Oral Tobacco Products segment retail share declined by 3.1 percentage points in the 4th quarter as declines in our MST brands were partially offset by on share gains. Within the MST category for the Q4 and full year, Copenhagen remained the undisputed leader and approximately 1 in every 2 MST cans purchased was a USSTC brand.

Turning to our investment in ABI, we recorded $159,000,000 of adjusted equity earnings for the 4th quarter, down 8.1% versus the prior year. These earnings reflect the impact of a lower ownership interest compared to the year ago period due to the partial sale of our ABI investment last year. We continue to view the ABI stake as a financial investment and our goal remains to maximize the long term value of the investment for our shareholders. We demonstrated our commitment to returning significant value to shareholders and maintaining a strong balance sheet during 2024. For the full year, we returned over $10,200,000,000 of cash to shareholders through dividends and share repurchases.

We paid $6,800,000,000 in dividends and our board raised our dividend by 4.1 percent in August, marking our 59th increase in the last 55 years. We also completed our previously authorized share repurchase program, repurchasing 73,500,000 shares for $3,400,000,000 representing our largest single year share repurchase in over 2 decades. Our share repurchases were supported by the proceeds from our partial sale of our investment in ABI. We effectively balanced our capital allocation priorities during the year and we maintained a strong balance sheet. Our total debt to EBITDA ratio as of December 31 was 2.1 times in line with our target of approximately 2 times.

Moving to 2025, I am pleased to announce that our board authorized a new $1,000,000,000 share repurchase program, which we expect to complete by the end of this year. With that, we'll wrap up and Billy and I will be happy to take your questions. While the calls are being compiled, I'll remind you that today's earnings release and our non GAAP reconciliations are available on altria. Com. We've also posted our usual quarterly metrics, which include pricing, inventory and other items.

Let's open the question and answer period. Operator, do we have any questions?

Thank you. We'll take our first question from Matt Smith with Stifel. Your line is open.

Hi, good morning. Billy, maybe to start out, the guidance for the year, the 2% to 5% EPS growth, can you talk about the phasing of earnings growth? You have lower MSA costs in the 1st 3 quarters, but one less shipping day in the Q1. So just as we consider the shape of the year, can you help us with in terms of phasing?

Yes. You know, Matt, we don't guide to the quarter. But I think as you think about the year, nothing is really distorting in 2024 as we look forward to 2025. You remember, 2024 to 2023, we ramped up spending in Enjoy because we had a half year to a full year ownership of that brand. Nothing like that would stand out for 2025 as we go forward.

We did want to highlight the one last shipping day in the Q1. So just to make sure people understood that that was occurring in the Q1.

Thank you, Billy. And as my follow-up, Marlboro continues to perform well in terms of market share of the premium segment, but discount share trends picked back up in the 4th quarter. You called out continued discretionary income pressure on adult tobacco consumers. Can you talk about the trends you're seeing in those adult consumers? Is there incremental pressure?

Is this continued cumulative impact over time and a mix shift given the proliferation of cigarette alternatives? And how do you see that playing out through 2025?

Yes. And that's one of the things we'll continue to monitor, Matt, to your point. We do see the cumulative impact really affecting our consumers. And you can see it outside of the tobacco industry. You can see it in credit card, late payments, things of that nature and the amount of credit card debt that consumers are carrying.

So the consumer continues to feel that pressure. And it really we believe is the cumulative impact of inflation. So we'll see how that shapes up in 2025. But we feel good about the guidance we gave. And as you know, take very many things into considerations before we provide that range.

But it is something that we'll monitor. As far as cross category, we're continuing to see that pressure. We try to highlight that in our decomposition of cigarette industry volume. It really is, and you heard in my remarks, the illicit vapor market flooding the market with flavors. If you step back, you can take an optimistic view.

It's what we've been saying that consumers are ready to move if they can find alternatives. We just need a regulatory system that authorizes legal products and enforces against illegal products.

Thank you. We'll take our next question from Bonnie Herzog with Goldman Sachs. Your line is open.

Good morning. I was hoping you could provide a little more color on the possible options you have for Enjoy and what a potential settlement would Juul be on the table. I guess, how are you guys thinking about playing in the e vapor category right now, especially given how the market has evolved with illicit, etcetera. Billy, you did discuss some of this and also asking given your comments about no longer being able to hit your targets for EnJoy. So is it maybe not worth being in e vapor right now and possibly better to prioritize and protect the profitability you have in smokeable, drive growth in NIC pouches with ON, as well as pursue HNB, while at the same time return cash to shareholders with your strong dividend and buyback program.

So just kind of love to hear your thoughts on all of this.

Yes. You brought up a lot of good points Bonnie. I'll try to give you a concise answer, but if I miss anything or you have follow-up, please do. I think when you step back as far as pathways, there are a number of pathways. There are still some steps in the process.

I talked about the review of the trade representative. While that has been if you look back in history, it's been very rare. I think there's special circumstances here. If you think about public health, you have a market that's flooded with illegal vapor products, specifically disposables that have completely shirked the regulatory process that are in the market. While you have Enjoy, which authorized on the tobacco flavors and the only authorized thus far on the menthol side.

So when I think you think about that from a public health perspective, I really believe public health and the improvement of public health through time should be a determining factor as we go through that process. But you mentioned settlement and you mentioned the factors that we'll be considering. 1, you need a reasonable party on the other side. We're going to be disciplined about it. When you think about the e vapor market, the pod segment declining at roughly 15%.

You have to be and we will be disciplined on what you consider reasonable. I think when you think about what's winning in the marketplace is illegal disposable products. And that's clearly the winner in the marketplace. The brands may change names, but that is what's winning it. So we're certainly taking that into consideration as we consider pipeline products to meet consumer demands in the e vapor space.

There are a number of avenues to continue. We've shared with you previously, we filed SD exemptions for 3 patents where we work our engineers work to not infringe on the patents. And I think when you come to the bottom line from the patent standpoint, nothing changes that goes into the product and nothing changes that comes out to the consumer. It's really some modifications to the device itself. And so I'll pause there and see if I hit all of your points, but that's how we're thinking about it.

No, I think that's helpful. But to your point about the SCs, I mean, I think what's maybe missing is that 4th, right? It doesn't solve for the 4th patent, I guess. So I think you're maybe still right? Okay.

Yes. I hear you, Bonnie. And their engineers are vigorously working on that final, if you will, change that would allow us not to infringe on the determination made by the ITC.

Okay. Thank you. And then maybe just another quick question from me, just on your guidance. First, I did want to verify that your guidance includes the likely potential you're going to have to pull EnjoyACE from the market at the end of March, I think it does. I just want to double check.

And then second, assuming that happens, is it realistic to think about your ability to hit the high end of your EPS guidance range or just that being more likely given that Enjoy is still operating at a loss and therefore has been a drag on earnings and if it's pulled that would actually boost your income this year?

Bonnie, we run as you know a number of scenarios as we're thinking about 2025. There are always puts and takes across the plan, and that's why we provided a range related to the EPS guidance. So we'll see how the year plays out. Obviously, we've got a lot of levers that we can pull to deal with anticipated variability in the marketplace. So we feel good about the guidance we've provided.

If there's anything to update as the year progresses, of course, we will.

Thank you. And we'll take our next question from vaham Bey with UBS. Your line is open.

Good morning, guys. I just have one follow-up and then maybe 2 actual questions. Just going quickly back to the question on Enjoy and the 4th patent that your engineers are furiously working behind. If you are able to successfully navigate that patent and are able to submit an SE application for that. By when do you expect to receive approval for that SE application?

And thereby, you could be able to bring that Enjoy product back on the market? The second question that I have was just on the Q4 results. And particularly in the smokeable division, your controllable costs in the final quarter was up around 13%, which is a sharp movement particularly from the previous quarter. Could you just maybe explain the dynamics in the Q4, which resulted into that as well as how we should think about controllable costs going into 2025? And the final question is on nicotine pouches.

I was a bit surprised that the oral tobacco category didn't grow faster in 'twenty five versus sorry, in 'twenty four versus 'twenty three given the rapid growth. But how do you see the growth of nicotine pouches in 2025 and particularly the competitive dynamics from both your legal players as well as some of the illicit ones?

Yes. I will answer the question on the 4th patent and the next team touches and then I'll let Sal answer the one on smokeable cost. I think when you think about that 4th patent, it really depends on the final lockdown of the change that we would make to be able to not infringe on the JUUL patent. If it follows the other 3, it would be through the SE exemption process. And as you recall, the SE exemption process is the more rapid, while not predictable, a more rapid process to get authorized by the FDA.

As far as nicotine pouches, I think as you see introductions of new categories, they always have fits and starts as far as growth depending on what consumer base they're reaching. I think you saw nicotine pouches grow so rapidly in the introduction because you had the traditional moist smokeless tobacco consumer moving over who was used to putting, if you will, tobacco or nicotine enjoyment products in their mouth. And so that's intuitive. I think what it will continue to grow is if it can speak to and consumers can make the change from other forms of nicotine such as cigarettes over to nicotine pouches. And so while we don't guide on volume, we think we have a great product with ON.

We're looking to ON plus to be authorized so that we can bring that to market and continue to engage the consumers to switch them over to smoke free products.

Yes. And in terms of costs, I think when you look at the Q4, I would just point to timing. I think you got to look at costs over a longer period than just 1 quarter. So timing definitely a factor in Q4. As far as 2025, we don't guide at that granularity of a level for controllable costs.

I will tell you though, obviously, we're the smokeable category is a declining category. We are going to be disciplined in how we think about resource allocation. I guess one other thing I would point to when it comes to cost management, there are controllable costs. And then of course, we are using data analytics and the revenue growth management tools to allow us to be more efficient with how we continue to allocate our promotional resources in support of our cigarette brands. So there's more than just controllable costs when we think about financial discipline.

Thank you. We'll take our next question from Gaurav Jain with Barclays. Your line is open.

Hi, good morning everyone. Thank you for taking my questions. So a few from me. So the first is on, you know your pricing was up nicely in Q4 and despite that the volume growth remains impressive. So is that something now how we should think of on that you can keep pricing up given especially the spread which still exists with the market leader and yet your volumes can continue to compound at the rate at which industry is growing?

Yes, I appreciate the question. I think when you think about the nicotine space, it's getting more and more competitive, both with illicit product in the marketplace as well as what we see is the FDA is applying enforcement discretion against synthetic nicotine products in the marketplace that had followed PMTA, even though it appeared that the statute was pretty clear. So I think their application of enforcement discretion has bled over to the synthetic in that area. I think when you think about O. N, I think it's the product itself.

It resonates with the consumer. We certainly have gotten a bit sharper with how we put promotional spending in the marketplace. It allows us to continue to generate trial while being able to increase, if you will, the profitability of the product in the marketplace. We were extremely pleased to be able to meet our profitability target ahead of time. And we'll continue to use that analytics to get sharper to generate trial, but to keep loyalty with the brand as well.

And you heard in the remarks, the loyalty percentage of the consumers year over year who are returning to purchase 1, we feel like is very impressive.

Thank you. Then a follow-up on actually your comments on the synthetic nicotine market. So clearly, your competitors are also launching the synthetic nicotine market. They are seeing the market differently in terms of what the FDA can do or cannot do. So isn't that a market you also want to participate in, not only on the nicotine pouch side, but also on the e cigarette side because a lot of new companies have launched a lot of using synthetic nicotine, then you should also be evaluating that.

Certainly. And we have been evaluating it all along. We were surprised with the application of enforcement discretion in that area based on the what we felt like was clarity in the statute when it was passed. But certainly with them applying enforcement discretion is something that's moved up on our radar.

Sure. And lastly on the cigarette market share losses, I think we all have discussed it over the years that you want to maximize profitability in cigarettes. But is there like larger share losses or worsening versus where the industry growth rate is? So does that start concerning you at some point of time?

I think when you back up, Gaurav, we've been highlighting for you that when you look historically, when the consumer is under pressure, they react to their current economic situation and you see some down trading that takes place. I think when you look at it historically, what you see is we certainly want to give consumers a safe place to stick with Marlboro because Marlboro is the aspirational brand. And you see us apply those tools. I think you see with the growth in premium through time of Marlboro that we've been applying those tools correctly. Certainly, as I highlighted, it's something that we'll continue to monitor.

Altria Group (MO) Q4 2024 Earnings Call Transcript

Company Participants